Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2017 San Antonio Breast Cancer Symposium
Oncology Conference Multimedia
View more videos >>
Dr. Burstein Discusses Key Updates from the SOFT Trial
Dr. Hershman Discusses Acupuncture for Arthralgia
Dr. Domchek Discusses Unanswered Questions from the MEDIOLA Trial
Oncology Conference Articles
Analysis Confirms Safety of Olaparib in Breast Cancer
An analysis of the phase III OlympiAD study showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy in patients with HER2-negative metastatic breast cancer and a germline
Olaparib/Durvalumab Combo Effective for BRCA-mutant Breast Cancer
The combination of olaparib (Lynparza) and durvalumab (Imfinzi) demonstrated a disease control rate of 80% for pretreated patients with germline
-mutated, HER2-negative metastatic breast cancer,
Abemaciclib/Pembrolizumab Combo Shows Early Promise for HR+/HER2- Breast Cancer
The combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.
Antibody-Drug Conjugate Active in Heavily Pretreated Metastatic TNBC
Monotherapy with an antibody drug conjugate targeting the transmembrane protein LIV-1 had encouraging antitumor activity in a phase 1 study of patients with heavily pretreated TNBC.
Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.
Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.
Positive CTC Findings Linked to High Recurrence Risk in HR+ Breast Cancer
Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer
Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset
Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.
Even Moderate Weight Loss Helps Prevent Breast Cancer in Postmenopausal Women
Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says.
Neoadjuvant Abemaciclib Active in Early Breast Cancer
Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.
CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival benefit similar to that seen in their younger counterparts
Talazoparib Improves PFS in BRCA-Positive Breast Cancer
The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.
Nab-Paclitaxel Improves DFS Over the Long Term in Early Breast Cancer
Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.
Nab-Paclitaxel Shows Greatest Utility for TNBC
Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer.
No Difference in Overall Survival with Shorter Extended AI Therapy
Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.
Acupuncture Reduces AI-Associated Joint Pain in Women with Breast Cancer
A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.
1-Year of Adjuvant Trastuzumab Remains Standard in HER2+ Breast Cancer
The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.
GnRHa May Protect Ovarian Function, Preserve Fertility in Premenopausal Women With Early-Stage Breast Cancer
Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.
Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer
Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.
Pembrolizumab/Trastuzumab Active in HER2-Positive Breast Cancer
The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.
Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes
Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.
Sacituzumab Govitecan Highly Effective in Heavily Pretreated mTNBC
Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.
Trastuzumab Disappoints in HER2-low Patient Cohort
A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.
OncLive News Network On Location: ASH 2019 Day 1
Lenalidomide Plus Obinutuzumab Achieves 100% ORR in Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Lenalidomide/Rituximab PFS Benefit Maintained in Elderly Subgroup With Indolent Non-Hodgkin Lymphoma
Anti-BCMA CAR-T JNJ-4528 Hits 100% Response Rate in Heavily Pretreated Myeloma
The KEYNOTE-146 Trial
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.